drugset / Trial / NCT05375760
A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19
RandomizedParallel-groupOpen-labelPrevention
Summary
A Phase II Randomized, Open-label, Multicenter, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, a Combination Product of Two Monoclonal Antibodies (Tixagevimab and Cilgavimab), for Pre-exposure Prophylaxis of COVID-19
Timeline
- Start
- 2022-06-09
- Primary completion
- 2023-10-04
- Completion
- 2023-10-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | cilgavimab | Monoclonal antibody | 150 mg | Intramuscular |
| Subject | cilgavimab | Monoclonal antibody | 300 mg | Intramuscular |
| Subject | tixagevimab | Monoclonal antibody | 150 mg | Intramuscular |
| Subject | tixagevimab | Monoclonal antibody | 300 mg | Intramuscular |